Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.

Biotechnology

Edgewise Therapeutics

Kevin Koch

Brooke Harrison

Matt M.

Kostas Kotselas

Zhou Jiang

Sherri Norland

Nicole Rempel Kilburn

Mike Carruthers

Maria Mancini

Marc Evanchik

Katherine Wilcox

Ericka Benson

Bruce D. Johnson

Badreddin Edris

Abby Bronson

The Research and Development Team at Edgewise Therapeutics is dedicated to innovating and advancing therapeutic solutions for skeletal muscle diseases. This multidisciplinary team collaborates on drug discovery, optimizing chemistry and manufacturing processes, and conducting preclinical studies to support the development of their lead product candidates for Duchenne and Becker Muscular Dystrophy, ensuring scientific rigor and regulatory compliance throughout the development pipeline.

Research and Development Team

Leadership Team

Clinical Operations Team

Research and Development Team

About

Team members

Other teams at Edgewise Therapeutics

Leadership Team

Clinical Operations Team